Form 4: IGM Biosciences CFO Misbah Tahir Reports Changes in Beneficial Ownership
SEC Form 4 Filing
IGM Biosciences' CFO, Misbah Tahir, reports the acquisition and disposal of restricted stock units (RSUs) and stock options as part of an option exchange program.
Summary
- On July 19, 2024, Misbah Tahir, CFO of IGM Biosciences, reported changes in beneficial ownership.
- Tahir acquired 33,111 RSUs that vest over time, starting July 19, 2025.
- Additionally, Tahir acquired 2,222 RSUs that vest over time, starting January 19, 2026.
- These transactions were part of an option exchange program where the company cancelled options to purchase 55,000 shares at $40.27 and 40,000 shares at $91.50.
- Following these transactions, Tahir directly owns 124,181 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing primarily reports routine transactions related to executive compensation. The option exchange program could be viewed slightly positively as it aligns incentives.
Positives
- The option exchange program may be seen as a positive move to align executive compensation with company performance through RSUs.
Future Outlook
The vesting schedules of the RSUs are contingent upon the Reporting Person remaining a service provider through each vesting date.
Industry Context
Option exchange programs are a common practice in the biotech industry to refresh equity incentives and align employee interests with shareholder value.
Comparison to Industry Standards
- Option exchange programs are frequently used by companies like Amgen, Gilead, and Biogen to manage their equity compensation and incentivize key employees.
- The vesting schedules for the RSUs are fairly standard, with vesting occurring over several years to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the option exchange program as a positive step towards aligning management incentives with company performance.
- Employees, particularly the CFO, are impacted by the changes in equity compensation.
Key Dates
| Date | Description |
|---|---|
| 07/19/2024 | Date of earliest transaction: Acquisition and disposal of RSUs and stock options. |
| 07/19/2025 | Vesting start date for one-half of the 33,111 RSUs. |
| 01/19/2026 | Vesting start date for one-half of the 2,222 RSUs. |
| 02/05/2030 | Original expiration date of options to purchase 55,000 shares of common stock at $40.27 (cancelled). |
| 02/19/2031 | Original expiration date of options to purchase 40,000 shares of common stock at $91.50 (cancelled). |
| 07/23/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.